Shanghai Shyndec Pharmaceutical 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Yong Liu

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	3.6yrs

최근 관리 업데이트

Recent updates

Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching

Nov 17

Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth

Oct 08

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Aug 23

Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified

May 06

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?

Apr 30

Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)

Apr 05

CEO

Yong Liu (55 yo)

less than a year

테뉴어

Mr. Yong Liu is Vice Chairman of the Board of Shanghai Shyndec Pharmaceutical Co., Ltd. from April 28, 2021 and serves as President Since September 2024.

리더십 팀

이름	위치	테뉴어	보상	소유권
Yong Liu	Vice Chairman of the Board & President	less than a year	데이터 없음	데이터 없음
Xian Lin Li	VP & General Counsel	2.6yrs	CN¥1.43m	0.0015% CN¥ 241.8k
Dongsong Wei	VP & Secretary of the Board of Directors	13.3yrs	CN¥1.46m	0.0015% CN¥ 241.8k
Feng Ni	Vice President	2yrs	CN¥914.60k	0.0015% CN¥ 241.8k
Jing Zu	Chief Financial Officer	less than a year	CN¥344.90k	데이터 없음

2.0yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: 600420 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yong Liu	Vice Chairman of the Board & President	3.6yrs	데이터 없음	데이터 없음
Yingqi Li	Independent Director	2yrs	CN¥240.00k	데이터 없음
Peng Wang	Director	2yrs	데이터 없음	데이터 없음
Ru Li	Director	2yrs	데이터 없음	데이터 없음
Zenghe Dong	Chairman	5.8yrs	데이터 없음	데이터 없음
Xiangdong Yu	Supervisor	5.8yrs	데이터 없음	0.0015% CN¥ 241.8k
Kan Tian	Independent Director	5.8yrs	CN¥240.00k	데이터 없음
Yonggang Xing	Chairman of the Supervisory Board	5yrs	데이터 없음	데이터 없음
Shuyuan Wei	Director	4.5yrs	데이터 없음	데이터 없음
Fanhong Wu	Independent Director	3.6yrs	CN¥240.00k	데이터 없음
Yonghua Zuo	Supervisor	2yrs	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: 600420 의 이사회는 경험(평균 재직 기간 3.6 년)으로 간주됩니다.

Shanghai Shyndec Pharmaceutical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Here's Why We Think Shanghai Shyndec Pharmaceutical (SHSE:600420) Is Well Worth Watching

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Shares Fly 35% But Investors Aren't Buying For Growth

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) Using Too Much Debt?

Investor sentiment improves as stock rises 17%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Improved Earnings Required Before Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) Stock's 33% Jump Looks Justified

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

Is Shanghai Shyndec Pharmaceutical (SHSE:600420) A Risky Investment?

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Solid Earnings May Not Tell The Whole Story For Shanghai Shyndec Pharmaceutical (SHSE:600420)

Full year 2023 earnings: EPS exceeds analyst expectations

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.076 in 1Q 2022)

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in FY 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that it has received CNY 1.199999999 billion in funding from China National Pharmaceutical Group Corporation

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.55 (vs CN¥0.63 in FY 2020)

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.63 (vs CN¥0.62 in FY 2019)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥8.47

New 90-day low: CN¥9.01

New 90-day low: CN¥9.42

New 90-day high: CN¥10.68

Third quarter earnings released

New 90-day low: CN¥9.49

First half earnings released

New 90-day high - CN¥10.64

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령